Manulife Pivots to Organic LTC Management after Third Reinsurance Deal

Biometric risk transfer preserves earnings and capital while derisking legacy block

MFC · Earnings Call · 2026-08-06

Strong Results, but a Structural Shift

Manulife's Q2 2026 results were broadly solid—APE sales up 21% YoY, core EPS up 16%, and core ROE at 16.3%. But the real narrative is the company's third long-term care (LTC) reinsurance transaction, announced with Munich Re. Unlike the prior two deals, this one is a stand-alone block with a full transfer of biometric risk on $3.2 billion of reserves at 80% quota share. The structure is telling: it's a pure risk transfer with no asset sale and no capital release. As Stephanie Fadous explained, "on an NAIC basis, the ceding commission would have been around 6% to 7%... we basically cede the biometric risk or exchange variable cash flows for fixed cash flows, but we retain the asset management." That retention is the key differentiator. The deal reduces Manulife's LTC morbidity risk by 24%, yet the capital impact is largely neutral. Phil Witherington emphasized that this is intentional: "through the biometric-only approach, it's not only that we retain the assets and therefore, an earnings and capital generation from that portfolio as it runs off... it's preserving profitability for Manulife." This is a marked departure from the first two transactions, which released significant capital and surrendered earnings, forcing the company to buy back stock to keep EPS flat. Colin Simpson made clear that buyback pace remains steady: "you see this year, 2.5%, that's without any boosting from reinsurance transactions."

The Third LTC Deal: Biometric Risk Without the Capital Release

The transaction's structure is a deliberate strategic choice. Forgoing the capital release avoids the earnings drag that plagued earlier deals. In the prior call, Marc Costantini had highlighted that the first two LTC transactions alone generated $2.8 billion of capital release, which funded aggressive buybacks. Now, by keeping the assets and the ALDA portfolio, Manulife preserves the earnings and the scale of its U.S. business—an explicit goal of the refreshed strategy. Phil's words capture the pivot:

When I reflect on what the best thing to do for Manulife shareholders is... now that we've demonstrated our ability to transact across various structures... I think the logical thing to do is to make that pivot to organic management while retaining the strategic flexibility to transact.
Philip Witherington, Senior Executive (likely CFO or similar) · 2026-08-06

The organic levers are already producing results. The LTC customer care program has delivered a 6% run-rate reduction in claims, and premium re-rates continue to be an effective mitigant. This new approach is also capital-efficient: the negative cede is modest, and there's no "noise" in core earnings or net income from the risk transfer.

Pivot to Organic Management and Its Implications

The shift has implications beyond LTC. It signals a more disciplined, shareholder-friendly approach to legacy portfolio management. The company can now preserve the earnings stream while reducing risk, rather than trading earnings for a one-time capital bump. This also relieves pressure on the share count. In the prior call, Phil had committed to completing the 2.5% NCIB "in full"; now he reaffirms that pace is sustainable without relying on reinsurance proceeds. Meanwhile, other themes persist: the Reinsurance Transaction is a recurring tool, but the emphasis is shifting. The high net worth and MCV business remains a growth driver, despite ongoing regulatory noise from China. Steven Finch noted that MCV is only 25% of Hong Kong sales and that the recent tax enforcement "hasn't destroyed the outlook." The company's diversified portfolio continues to absorb shocks, from Canada's group LTD claims to corporate expenses tied to AI investments. Overall, the third LTC deal is less about the deal itself and more about the strategic pivot it signals. Manulife is maturing into a phase where organic capital generation and efficient risk transfer coexist, and investors should watch how this balances against the 18% ROE target.